1University of Alabama at BirminghamFeb 18, 2026·also Baylor Scott and White Health, The University of Alabama, UF, University of Alabama at Birmingham
Identifying genomic and spatial immune signatures predictive of response to neoadjuvant chemoimmunotherapy in TNBC could lead to a multimodal biomarker to guide treatment optimization.